BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37921068)

  • 21. [Synergistic effect of polysaccharide from
    Li P; Yuan P; Que Y; Liu X; Wang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):504-513. PubMed ID: 33963708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells.
    Poel D; Boyd LNC; Beekhof R; Schelfhorst T; Pham TV; Piersma SR; Knol JC; Jimenez CR; Verheul HMW; Buffart TE
    Cells; 2019 Sep; 8(9):. PubMed ID: 31546954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
    Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
    J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage.
    Gong H; Cao Y; Han G; Zhang Y; You Q; Wang Y; Pan Y
    Int J Oncol; 2017 May; 50(5):1785-1791. PubMed ID: 28339062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p.
    Ghanbarian M; Afgar A; Yadegarazari R; Najafi R; Teimoori-Toolabi L
    Biomed Pharmacother; 2018 Dec; 108():1070-1080. PubMed ID: 30372807
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
    Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
    Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Cyanidin-3-
    Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
    Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
    Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.
    Zhang Y; Geng L; Talmon G; Wang J
    J Biol Chem; 2015 Mar; 290(10):6215-25. PubMed ID: 25616665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxaliplatin-loaded nanoemulsion containing
    Al-Otaibi WA; AlMotwaa SM
    Drug Deliv; 2022 Dec; 29(1):2190-2205. PubMed ID: 35815706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.
    Wang M; Xiang Y; Wang R; Zhang L; Zhang H; Chen H; Luan X; Chen L
    Molecules; 2022 Nov; 27(22):. PubMed ID: 36431875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.
    Zhang Y; Liu X; Zhang J; Xu Y; Shao J; Hu Y; Shu P; Cheng H
    Aging (Albany NY); 2020 Mar; 12(7):5640-5650. PubMed ID: 32209726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
    Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
    Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
    Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
    Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MiR-744 mediates the Oxaliplatin chemoresistance in colorectal cancer through inhibiting BIN1.
    Zhou Y; He A; Zhang L; Yi G
    Neoplasma; 2020 Mar; 67(2):296-303. PubMed ID: 31884801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell.
    Wang Z; Sun X; Feng Y; Wang Y; Zhang L; Wang Y; Fang Z; Azami NLB; Sun M; Li Q
    Phytomedicine; 2021 Feb; 82():153414. PubMed ID: 33461143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription.
    Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z
    Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor circPDE4D inhibits the progression of colorectal cancer and regulates oxaliplatin chemoresistance.
    Li J; Lv J; Chen Y; Li L
    Gene; 2023 May; 864():147323. PubMed ID: 36858188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.